Drug Trial Radar · NCT01853124
Emergency Department Probiotic Treatment of Pediatric Gastroenteritis
Last checked: Nov 19, 2026Latest source record: Mar 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
886
Actual
Start
Nov 2013
Primary completion
May 2017
Study completion May 2017
Sponsor
- Lead sponsor
- Dr. Stephen FreedmanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital; The Hospital for Sick Children; Children's Hospital of Eastern Ontario; St. Justine's Hospital; IWK Health Centre; Institut Rosell Lallemand; London Health Sciences Center, Children's Hospital
- First posted
- May 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 months, up to 48 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to determine for previously healthy children who present to a Canadian Emergency Department (ED) with acute gastroenteritis (infection or irritation of the digestive tract); if compared with placebo, the administration of a probiotic agent (Lacidofil) will result in a significantly lower proportion of children developing moderate to severe disease over the subsequent 2 weeks and will not be associated with a significantly greater occurrence of side effects.
Conditions
- Gastroenteritis
Interventions
PlaceboDrug
All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
LacidofilDrug
All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development of moderate to severe disease in the 2 weeks after the index visitTime frame: Measured daily for 14 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Alberta Children's Hospital
Calgary, Alberta, Canada
IWK Health Centre
Halifax, Nova Scotia, Canada
Children's Hospital, London Health Sciences Center
London, Ontario, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
Centre Hospitalier Universitaire Sainte Justine
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.